What is HC Wainwright’s Estimate for SXTP Q4 Earnings?

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) – Investment analysts at HC Wainwright reduced their Q4 2024 EPS estimates for shares of 60 Degrees Pharmaceuticals in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst E. White now expects that the company will post earnings of ($4.77) per share for the quarter, down from their previous estimate of ($4.75). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ FY2025 earnings at ($3.59) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, February 19th.

60 Degrees Pharmaceuticals Stock Up 4.7 %

Shares of 60 Degrees Pharmaceuticals stock opened at $2.01 on Thursday. 60 Degrees Pharmaceuticals has a 12 month low of $1.78 and a 12 month high of $35.99. The stock has a market cap of $2.96 million, a PE ratio of -0.20 and a beta of 4.22. The business has a fifty day simple moving average of $4.41 and a 200-day simple moving average of $5.52.

Insider Buying and Selling

In related news, CEO Geoffrey S. Dow bought 7,164 shares of the business’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $6.35 per share, for a total transaction of $45,491.40. Following the transaction, the chief executive officer now directly owns 18,916 shares in the company, valued at $120,116.60. This represents a 60.96 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders purchased 12,073 shares of company stock worth $76,966. 10.27% of the stock is owned by company insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.